89bio, Inc. (ETNB) Reports Second-Quarter Results; Leerink Partners and Citi Maintain 'Buy' Ratings

With significant hedge fund interest and a share price under $10, 89bio, Inc. (NASDAQ:ETNB) secures a spot on our list of the 11 Best Single Digit Stocks to Buy According to Hedge Funds.

On August 7, 2025, 89bio, Inc. (NASDAQ:ETNB) reported its Q2 2025 results. The company highlighted steady progress across three global Phase 3 trials for pegozafermin, a drug that aims to treat severe metabolic issues. ETNB expects to release the main results for the ENTRUST trial in severe hypertriglyceridemia (very high blood triglyceride levels) by Q1 2026; meanwhile, the company expects to deliver histology results for the ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis MASH studies by 1H 2027 and 2028, respectively. Its development programs and a commercial-scale production facility build-out are supported well by its cash and marketable securities balance of $561.2 million as of the quarter-end.

Meanwhile, analyst sentiment remains mixed following the results. Leerink Partners, on August 7, and Citi, on August 8, kept their ‘Buy’ ratings on 89bio, Inc. (NASDAQ:ETNB) with $37 and $11 price targets, respectively. At the same time, RBC Capital maintained its ‘Hold’ rating on August 8 with an $11 target.

89bio, Inc. (NASDAQ:ETNB), a biopharmaceutical company, treats liver and cardiometabolic diseases. It is included in our list of the Best Single Digit Stocks.

While we acknowledge the potential of ETNB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Gold Penny Stocks to Buy According to Hedge Funds and 11 Best Rebound Stocks to Buy According to Hedge Funds.

Disclosure: None.